Company news

Cumberland Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cumberland Pharmaceuticals announces plans to file New Drug Application for ifetroban DMD program

October 26, 2026

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

October 23, 2026

Cumberland Pharmaceuticals provides updated webcast registration link for ifetroban dmd program call

October 23, 2026

Cumberland Pharmaceuticals announces national call to present an update on its ifetroban dmd program

October 19, 2026

Cumberland Pharmaceuticals reports company update & Q2 2026 financial results

August 4, 2026

Cumberland Pharmaceuticals to announce company update & Q2 2026 financial results

July 28, 2026

Cumberland Pharmaceuticals announces special dividend of $1.50 per share

July 13, 2026

Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

July 1, 2026

Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

June 26, 2026

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

June 2, 2026

Cumberland Pharmaceuticals announces launch of Vibativ® in China

May 28, 2026

Cumberland Pharmaceuticals reports Q1 2026 financial results & company update

May 5, 2026

Cumberland Pharmaceuticals to announce Q1 2026 financial results & company update

April 28, 2026

Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex

April 23, 2026

Cumberland Pharmaceuticals announces expanded indication for Caldolor® (ibuprofen) injection and launch of new brand website

April 15, 2026

Cumberland Pharmaceuticals Launches New Sancuso Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

March 18, 2026

Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

March 17, 2026

Annual Report for Fiscal Year Ending 12-31, 2025 (Form 10-K)

March 9, 2026

Cumberland Pharmaceuticals reports 31% fourth quarter 2025 revenue growth

March 2, 2026

Cumberland Pharmaceuticals launches U.S. promotion of Talicia®

February 24, 2026

Cumberland Pharmaceuticals to announce 2025 annual financial results & company update

February 24, 2026

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

February 4, 2026

Caldolor® (ibuprofen) injection cms issued J-Code now associated with reimbursement price supporting non-opioid pain management

December 8, 2025

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

December 1, 2025

Cumberland Pharmaceuticals reports 12% year-to-date revenue growth

November 4, 2025

Cumberland Pharmaceuticals to announce Q3 2025 financial results & company update

October 28, 2025

RedHill Biopharma Receives Nasdaq Staff Determination Notification

October 22, 2025

Cumberland phamaceuticals announces the addition of an established FDA approved product to its commercial portfolio

October 20, 2025

Cumberland Pharmaceuticals' Vibativ® added to national group purchasing agreement with Premier, inc.

October 13, 2025

Cumberland Pharmaceuticals announces product approval in Mexico

October 1, 2025

Tabuk launches Vibativ® FDA-approved antibiotic with life-saving potential in Saudi Arabia

September 29, 2025

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

August 5, 2025

Cumberland Pharmaceuticals receives Vizient contract for new Vibativ® 4-Vial Starter Pak

August 4, 2025

Cumberland Pharmaceuticals to announce Q2 2025 financial results & company update

July 29, 2025

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

June 23, 2025

New study finds Caldolor® safe and effective for opioid-sparing pain management in older adults

May 27, 2025

Cumberland Pharmaceuticals partners with Qureight to advance innovative idiopathic pulmonary fibrosis treatment research

May 13, 2025

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

May 6, 2025

Cumberland Pharmaceuticals to announce Q1 2025 financial results & company update

April 29, 2025

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

March 19, 2025

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

March 4, 2025

Cumberland Pharmaceuticals to announce annual 2024 financial results

February 25, 2025

Vibativ® receives marketing approval in China

February 18, 2025

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

February 3, 2025

FDA approves Acetadote® sNDA

December 8, 2024

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

November 6, 2024

Cumberland Pharmaceuticals receives FDA Orphan Drug and rare pediatric disease designations for new treatment of Duchenne muscular dystrophy

November 5, 2024

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

August 5, 2024

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

May 6, 2024

Cumberland Pharmaceuticals to announce first quarter 2024 financial results

April 29, 2024

Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.